These showed that imatinib, nilotinib, dasatinib, and bosutinib were taken by CML patients, over time had caused inhibition to CML cell proliferation, led to apoptosis, and thus reduced the amount of BCR-ABL1 in CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.